AzTrials
AzTrials

ASD2(Secundum Atrial Septal Defect)NCT07823972

Dapagliflozin and Right Heart Recovery After ASD Device Closure

A study testing trans catheter device closure in people with ASD2(Secundum Atrial Septal Defect), run by Assiut University at 1 site in Egypt.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record

Search all trials

Trial summary

The aim of this study is to evaluate the clinical and echocardiographic influence of dapagliflozin on right ventricular reverse remodeling in adult patients following successful transcatheter Atrial Septal Defect (ASD) device closure. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
ASD2(Secundum Atrial Septal Defect)
What is being tested?
trans catheter device closure
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
70 participants
Where
1 siteEgypt
Study dates
1 Nov 2026to 30 Jan 2029
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • 1. Adults with ASD and significant left to right shunt which is anatomically suitable for transcatheter device closure.
  • 2. Adults (age ≥18 years) of both genders. 3. Sinus rhythm on presentation.

Who cannot join

  • 1. Presence of other congenital anomalies e.g. AV canal, CoA, VSDs, PDA, dextrocardia.
  • 2. Significant irreversible pulmonary hypertension (PVR ≥ 5 wood units) or Eisenmenger syndrome.
  • 3. Patients presented with arrythmias (especially atrial fibrillation). 4. Severe left ventricular systolic dysfunction (LV ejection fraction (< 50%). 5. Significant Valvular Heart Disease. 6. Patients known to have history of ischemic heart disease or percutaneous coronary interventions.
  • 7. Severely impaired renal function defined as an estimated glomerular filtration rate (eGFR) (< 30 mL/min/1.73m²) 8. Patients with contraindications for SGLT2i: Type 1 diabetes mellitus, history of diabetic ketoacidosis, recurrent severe urinary tract infections, active genital mycotic infections, or known hypersensitivity to dapagliflozin.
  • 9. Poor-quality Echocardiography images precluding strain analysis

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

nada deyaa, master contact

0201060123997

nada.deyaaa@yahoo.com

Egypt1 site
  • Assiut university

    Asyut

    Heba Elnaggar, Associate professor, 01001963100 ext. 01001963100, heba_m_elnaggar@yahoo.com

    Mohamed Osman, lecturer, m.osman@aun.edu.eg

Other trials in Egypt

About this study

Official title: Impact of Dapagliflozin Therapy on Right Ventricular Remodeling Following Transcatheter Atrial Septal Defect Closure in Adults: Randomized Clinical Trial

The aim of this study is to evaluate the clinical and echocardiographic influence of dapagliflozin on right ventricular reverse remodeling in adult patients following successful transcatheter Atrial Septal Defect (ASD) device closure.

Read the detailed description

All patients will be subjected to:

  1. Detailed medical history review, clinical evaluation, 12- lead ECG before intervention.
  2. Full Laboratory investigations: Preoperative standard Lab Screening: CBC, liver function tests (ALT, AST), coagulation profile, HbA1c, serum creatinine and blood urea nitrogen. The estimated glomerular filtration rate (eGFR) will be calculated using the MDRD or CKD-EPI formula to confirm compliance with the inclusion threshold (≥ 30 mL/min/1.73m²).
  3. Echocardiography (TTE):
  • ASD size, anatomy and direction of shunting (better assessment using TEE if available), Screening for other congenital anomalies.
  • RV dimensions: basal and mid-cavity RV dimensions are measured in RV focused apical view.
  • RV function: by measurement of tricuspid annular plane systolic excursion (TAPSE), fractional area change (FAC) and tricuspid systolic (S') peak velocity by Tissue Doppler Imaging (TDI), were made according to the guidelines . RVFAC is considered normal when > 35%. TAPSE is considered normal when > 16 mm. S' with a value below 10 cm/s suggesting systolic dysfunction.
  • Tricuspid regurgitation severity, calculation of RVSP from TR velocity.
  • LV dimensions and volumes.
  • LV systolic function using Simpson's method.
  • LV diastolic function.
  1. 2D Speckle Tracking Echocardiography ( 2D STE):
  • electrocardiographic - gated acquisition of 3- beat loops for standard echocardiographic views, including apical 4 chamber view, apical 2 chamber view, apical 3 chamber view and RV-focused apical 4 chamber view, all obtained in a frame rate between 60- 90 fps [12] for offline analysis.
  1. Right Ventricular (RV) Strain Analysis o Right Ventricular Free Wall Longitudinal Strain (RVFWLS) will be calculated using a dedicated, non-foreshortened RV-focused apical 4-chamber view.
  2. Left Ventricular (LV) Strain Analysis
  • Left Ventricular Global Longitudinal Strain (LVGLS) will be calculated using standard apical 4-chamber, 2-chamber, and 3-chamber views to derive a complete 17-segment peak systolic strain assessment.
  1. Left Atrial (LA) Strain Analysis
  • Left Atrial Strain tracking will be conducted on standard, non-foreshortened apical 4-chamber and 2-chamber cine loops optimizing the LA boundaries. [12]
  • Phasic Parameter Extraction: Three distinct phasic strain components will be exported from the generated software strain curves: LA Reservoir Strain, LA Conduit Strain, LA Contraction Strain
  1. Functional capacity assessment:
  • All patients will be classified according to NYHA classification and will undergo 6-Minute Walk Test (6MWT) will evaluate functional distance 12]. also will be evaluated by the Kansas City Cardiomyopathy Questionnaire (KCCQ)
  1. Intra- procedural assessment: In the catheterization laboratory, ASD closure will be performed under general anesthesia guided by TEE to assess the following: ASD anatomy and size, Mitral and tricuspid regurgitation and its degree, Hemodynamics study, assessment of device size, type of the device.
  2. Randomization and treatment allocation - Following successful transcatheter closure and stabilization (typically 24-48 hours post-procedure), eligible patients will be randomized in a 1:1 ratio into one of two parallel groups using a manual allocation, sequentially numbered, opaque, sealed envelopes (SNOSE):
  • Intervention Group (Dapagliflozin): Patients will receive oral Dapagliflozin 10 mg once daily in addition to standard post-closure medical care (e.g., antibiotics, dual antiplatelet therapy and anti-failure treatment if indicated).
  • Control Group: Patients will receive standard post-closure medical therapy alone. The total planned duration of active pharmacological follow-up is 6 months
  1. Follow up of the cases after 3 and 6 months': All patient with be subjected to the following:
  • The functional capacity assessment with the same methods: NYHA Class, 6 WMT distance, KCCQ.
  • Transthoracic Echocardiography with the same measurements which assessed before closure.
  • 2D Speckle Tracking Echocardiography with the same measurements which assessed before closure.
Being tested
trans catheter device closure
Medical subject headings
Foramen Ovale, Patent

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • trans catheter device closureDevice

    randomized clinical trila

Study groups in NCT07823972
Study groupRoleWhat they receive
dapagliflozin armActive comparatorgiven dapagliflozin post ASD closure
Receives: Device: trans catheter device closure
controlPlacebo comparatorgiven regular treament post ASD closure
Receives: Device: trans catheter device closure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. RV strain

    Assess changes in Right Ventricular Free Wall Longitudinal Strain (RVFWLS) using 2D speckle-tracking echocardiography over a 6-month post-procedural period.

    Measured: follow up after 3 and 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Sep 2026
  2. Study start1 Nov 2026 (estimated)
  3. Primary completion1 Sep 2028 (estimated)
  4. Study completion30 Jan 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
70 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07823972
Sponsor's protocol ID
not yet submitted
Status last verified
Sep 2026
First submitted
11 Sep 2026
Last updated
17 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in